Boston Scientific Logo

1999 -1990

1990
  • Boston Scientific goes public with an IPO on the New York Stock Exchange. Its symbol is BSX.


  • The United States Food and Drug Administration cites Mansfield's pioneering efforts in the development and the evaluation of valvuloplasty as one of the nine most significant regulatory approvals of the year.


  • EP Technologies' first two-way steerable catheter is released.
1991
  • A new plant to support the rapidly growing urology business takes shape in Indiana.
1992
  • Boston Scientific goes public with an IPO on the New York Stock Exchange. Its symbol becomes BSX.


  • The Mansfield EP division is formed to focus on electrophysiology.


  • David Auth, creator of the Rotablator®, takes Heart Technology public.


  • Gastrointestinal endoscopy is the fastest growth area for Boston Scientific.


  • All Boston Scientific employees become shareholders through a company gift of stock at the end of the year.
1993
  • The United States Food and Drug Administration approves Synergy, the first in a family of new-generation convertible PTCA catheter systems under development at Boston Scientific.


  • Boston Scientific begins expanding in Spencer, Indiana, and Denmark.


  • Jean Baptiste Honore of France, at 89 years old, receives the first Boston Scientific percutaneous aneurysm graft and returns to his normal routine in three days.


  • Heart Technology's Rotablator® receives FDA approval for use in coronary arteries.


  • Boston Scientific's regional headquarters are established in Japan.


  • Boston Scientific buys 35 acres in Natick, Massachusetts, to house its Global Corporate Headquarters.
1994
  • The company holds 90 U.S. and 85 foreign patents and has pending 102 U.S. and 131 foreign patent applications.


  • The new manufacturing facility in Galway, Ireland, begins shipping products.


  • Boston Scientific is number eight on the Boston Globe's Top 100 list.


  • Microvasive Endoscopy receives United States Food and Drug Administration approval in September to market the Ultraflex™ esophageal stent system for treatment of advanced esophageal cancer.


  • EP Technologies is the first to receive United States Food and Drug Administration approval for a cardiac ablation system for treatment of supraventricular tachycardias.
Additional Information
“It's interesting to look back at how we originally characterized who Boston Scientific was, what we did, what was important. It hasn't changed a bit, that's because the values are timeless ones: people, passion, commitment, conviction, integrity and a focus on patients.”

PETE NICHOLAS
Founder, Director and Chairman of the Board

“When we started out, the potential of less-invasive medicine to reduce risk, trauma, cost, time and aftercare was not obvious to many. But anytime someone challenges the established way of doing things, it's not welcomed right away. You have to be patient. We're still trying to convert marketplaces all over the world and in many different specialties. We're doing it with one goal in mind: providing benefits to doctors, to patients and, frankly, to society overall.”

JOHN ABELE
Founder, Director